First Tracks Biotherapeutics (TRAX) — Strategic Asset Allocation Index
First Tracks Biotherapeutics (TRAX) has a Strategic Asset Allocation Index of 9.1% as of December 2024. Strategic assets (PP&E of $- plus long-term investments of $35.47 Million) total $35.47 Million, measured against net assets of $391.60 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. For live market cap and overall valuation, see TRAX stock market capitalisation.
SAAI
Strategic Assets
PP&E
Net Assets
First Tracks Biotherapeutics Strategic Asset Allocation Index (2023–2024)
This chart shows how First Tracks Biotherapeutics's Strategic Asset Allocation Index has evolved across 2 annual periods from 2023 to 2024. As of December 2024, the index stands at 9.1%, representing strategic assets of $35.47 Million against net assets of $391.60 Million USD. See First Tracks Biotherapeutics (TRAX) net asset quality to measure how much of total assets are equity-financed.
Annual Strategic Asset Allocation Index for First Tracks Biotherapeutics (2023–2024)
The table below presents the year-by-year Strategic Asset Allocation Index for First Tracks Biotherapeutics from 2023 to 2024, covering 2 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. Also explore TRAX net assets growth trend to track the company's year-over-year net asset growth rate.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 9.1% | $35.47 Million | $- | $35.47 Million | $391.60 Million | ▲ +2.5 pp |
| 2023 | 6.6% | $27.03 Million | $- | $27.03 Million | $409.85 Million | — |